TNF[alpha]-inhibition in the treatment of rheumatoid arthritis
Author(s)
Bibliographic Information
TNF[alpha]-inhibition in the treatment of rheumatoid arthritis
Martin Dunitz, 2003
Available at 4 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Note
Includes bibliographical references and index
Description and Table of Contents
Description
The introduction of tumor-necrosis-factor-alpha (TNFa) blocking agents is one of the milestones in the therapy of rheumatoid arthritis (RA). Edited by Larry Moreland and Paul Emery, experts in rheumatological disease, TNFa-Inhibition in the Treatment of Rheumatoid Arthritis charts the history and development of the concept of TNFa inhibition. The authors document TNFa from its discovery to its now well-documented clinical applications in the treatment of patients with RA. They compare and contrast practical management issues concerning the use of these agents both in the US and UK/Europe. The book is a practical and accessible source containing the most recent information in this field.
Table of Contents
Definition of TNFa as a Therapeutic Target for Rheumatoid Arthritis, M. Feldman, F.M. Brennan, R.O. Williams, and R.N. Maini
Infliximab Therapy, R.N. Maini and M. Feldman
Etanercept, S.Sule and J.M. Bathan
Adalimumab, L. van de Putte, J. Salfeld, and S. Kaymakcalan
p-55 TNF Receptor Therapy, J.J. Cash
TNFa-Inhibition in Practical Management of Rheumatoid Arthritis: The US Model, J.C. Shanahan and L.W. Moreland
TNFa-inhibition in Practical Management: The UK/European Model, P. Emery
Safety Issues with Anti-TNF Agents: Immunomodulation and Infection, J.C. Shanahan
Index
by "Nielsen BookData"